When is antipsychotic polypharmacy supported by research evidence? Implications for QI

Joint Commission Journal on Quality and Patient Safety

Volumn 34, Issue 10, 2008, Pages 571-582

  Gören, Jessica L ^a,b,c   Parks, Joseph J ^d,e   Ghinassi, Frank A ^f,g   Milton, Celeste G ^h   Oldham, John M ^i,j   Hernandez, Pablo ^k   Chan, Jeffrey ^l   Hermann, Richard C ^l,m  

^a UNIVERSITY OF RHODE ISLAND   (United States)

^b CAMBRIDGE HEALTH ALLIANCE   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d Dept Psychiat Psychol Pediat   (United States)

^e University of Missouri   (United States)

^f UNIVERSITY OF PITTSBURGH   (United States)

^g UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^h Division of Quality Measurement and Research   (United States)

ⁱ MENNINGER CLINIC   (United States)

^j BAYLOR COLLEGE OF MEDICINE   (United States)

^k GeoGroup Inc   (United States)

^l TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^m VA BOSTON HEALTHCARE SYSTEM   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT;

EVIDENCE BASED MEDICINE; HUMAN; POLYPHARMACY; REVIEW;

ANTIPSYCHOTIC AGENTS; EVIDENCE-BASED MEDICINE; HUMANS; POLYPHARMACY;

EID: 55349139334     PISSN: 15537250     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1553-7250(08)34072-0     Document Type: Article

References (83)

1. Lieberman J.A., et al.: Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Eng J Med 353:1209-1223, Sep. 26, 2005.
2. Zyprexa [package insert]. Indianapolis, IN: Eli Lilly and Company, 2007.
3. Risperdal [package insert]. Titusville, NJ: Janssen LP, 2007.
4. Seroquel [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals, 2008.
5. Abilify [package insert]. Princeton, NJ: Bristol Myers Squibb, 2007.
6. Symbyax [package insert]. Indianapolis, IN: Eli Lilly and Company, 2008.
7. Centorrino F., et al.: Use of combination antipsychotics: McLean Hospital inpatients, 2002. Hum Psychopharmacol 20:485-492, Oct. 20, 2005.
8. Jaffe A.B., et al.: Antipsychotic medication co-prescribing in a large state hospital system. Pharmacoepidemiol Drug Saf 12:41-48, Jan.-Feb. 2003.
9. Centorrino E., et al.: Hospital use of antipsychotic drugs: Polytherapy. Compr Psychiatry 49:65-69, Jan.-Feb. 2008.
10. Procyshyn R.M., et al.: Antipsychotic polypharmacy: A survey of discharge prescriptions from a tertiary care psychiatric institution. Can J Psychiatry 46:334-339, May 2001.
11. Centorrino F., et al.: Antipsychotic drug use, McLean Hospital, 2002. Hum Psychopharmacol 20:355-359, Oct. 2005.
12. Grohmann R., et al.: Psychotropic drug use in psychiatric inpatients: recent trends and changes over time - Data from the AMSP study. Pharmacopsychiatry 37(suppl. 1):S27-S38, Mar. 2004.
13. Covell N.H., et al.: Antipsychotic prescribing practices in Connecticut's public mental health system: Rates of changing medication prescribing styles. Schizophr Bull 28(1):17-29, 2002.
14. Ganguly R., et al.: Prevalence, trends, and factors associated with antipsychotic polypharmacy among Medicaid-eligible schizophrenia patients, 1998-2000. J Clin Psychiatry 65:1377-1388, Oct. 2004.
15. Gilmer T.P., et al.: Antipsychotic polypharmacy trends among Medicaid beneficiaries with schizophrenia in San Diego County, 1999-2004. Psychiatr Serv 59:1007-1010, Jul. 2007.
16. Thompson A., et al.: The DEBIT trial: An intervention to reduce antipsychotic polypharmacy prescribing in adult psychiatry wards - A cluster randomized controlled trial. Psychol Med 10:1-11, May 2008.
17. Edlinger M., et al.: Trends in the pharmacologic treatment of patients with schizophrenia over a 12 year observation period. Schizophr Res 77(1):25-34, 2005.
18. Rittmannsberger H., et al.: Polypharmacy in psychiatric treatment: Patterns of psychotropic drug use in Austrian psychiatric clinics. Eur Psychiatry 14:33-40, Mar. 1999.
19. Chong S.A., et al.: Reducing polypharmacy through the introduction of a treatment algorithm: Use of a treatment algorithm on the impact of polypharmacy. Ann Acad Med Singapore 35:457-460, Jul. 2006.
20. Biancosino B., et al.: Determinants of antipsychotic polypharmacy in psychiatric inpatients: A prospective study. Int Clin Psychopharmacol 20:305-309, Nov. 2005.
21. Procyshyn R.M., et al.: Patterns of antipsychotic utilization in a tertiary care psychiatric institute. Pharmacopsychiatry 37:12-17, Jan. 2004.
22. McCue R.E., et al.: Polypharmacy in patients with schizophrenia. J Clin Psychiatry 64:984-989, Sep. 2003.
23. Hamann J., et al.: Antipsychotic prescribing patterns in Germany: A retrospective analysis using a large outpatient database. Int Clin Psychopharmacol 18:237-242, Jul. 2003.
24. Humberstone V., et al.: An audit of outpatient antipsychotic usage in three health sectors of Auckland, New Zealand. Aust NZ J Psychiatry 38:240-245, Apr. 2004.
25. Kreyenbuhl J., et al.: Long-term combination antipsychotic treatment in VA patients with schizophrenia. Schizophr Res 84:90-99, May 2006.
26. Tapp A., et al.: Combination antipsychotic treatment in clinical practice. Psychiatr Serv 54:55-59, Jan. 2003.
27. Tempier R.P., et al.: Conventional, atypical, and combination antipsychotic prescriptions: A 2 year comparison. J Clin Psychiatry 64:673-679, Jun. 2003.
28. Weissman E.M.: Antipsychotic prescribing practices in the Veteran Healthcare Administration-New York metropolitan region. Schizophr Bull 28(1):31-42, 2002.
29. Schumacher J.E., et al.: Multiple antipsychotic medication prescribing patterns. Ann Pharmacother 37:951-955, Jul.-Aug. 2003.
30. Taylor D., et al.: Co-prescribing of atypical and typical antipsychotics-Prescribing sequence and documented outcome. Psychol Bull 26:170-172, May 2002.
31. Ning A., et al.: Pharmacy costs: Finding a role for quality. Psychiatr Serv 56:909-911, Aug. 2005.
32. Stahl S.M., et al.: High-cost use of second generation antipsychotics under California's Medicaid Program. Psychiatr Serv 57:127-129, Jan. 2006.
33. Barbui C., et al.: Persistence with polypharmacy and excessive dosing in patients with schizophrenia treated in 4 European countries. Int Clin Psychopharmacol 21:355-362, Nov. 2006.
34. Sabin J.E., et al.: Improving psychiatric drug benefit management: Lessons from Massachusetts. Psychiatr Serv 54:949-951, Jul. 2003.
35. National Association of State Mental Health Program Directors Research Institute, Inc. (NRI): NRI Projects: Behavioral Healthcare Performance Measurement System. http://www.nri-inc.org/projects/BHPMS/morebhpms. cfm (last accessed Aug. 21, 2008).
36. The Joint Commission: Specification Manual for National Quality Measures - Hospital-Based Inpatient Psychiatric Services Psychiatric Core Measure Set (Version 2.0a), Jul. 2008. http://www.jointcommission.org/ PerformanceMeasurement/PerformanceMeasurement/Hospital+Based+ Inpatient+Psychiatric+Services.htm (last accessed Aug. 20, 2008).
37. Diaz E., et al.: Adherence to conventional and atypical antipsychotics after hospital discharge. J Clin Psychiatry 65:345-360, Mar. 2004.
38. Patel M.X., et al.: Medication adherence: Predictive factors and enhancement strategies. Psychiatry 6:357-361, Sep. 2007.
39. Sabin J.E., et al.: Public-sector managed behavioral health care: II. Contracting for Medicaid services - The Massachusetts experience. Psychiatr Serv 50:39-41, Jan. 1999.
40. Sabin J.E., et al.: Improving psychiatric drug benefit management: III. The VA's approach to atypical antipsychotics. Psychiatr Serv 55:22-25, Jan. 2004.
41. Hermann R.C.: Improving Mental Healthcare: A Guide to Measurement-Based Quality Improvement. Washington, DC: American Psychiatric Publishing, Inc., 2005.
42. American Psychiatric Association: Practice guideline for the treatment of patients with schizophrenia. American Psychiatric Association. Am J Psychiatry 161(suppl. 2):1-56, Feb. 2004.
43. Moore, et al.: The TMAP Schizophrenia Algorithms, 2006 update. J Clin Psychiatry 68:1751-1762, Nov. 2007.
44. National Institute for Health and Clinical Excellence: Schizophrenia: Core Interventions in the Treatment and Management of Schizophrenia in Primary and Secondary Care. 2002. http://www.nice.org.uk/guidance/index.jsp? action=byID&r=true&o=10916 (last accessed Feb. 2, 2008).
45. Stahl S.M., et al.: A critical review of atypical antipsychotic utilization: Comparing monotherapy with polypharmacy and augmentation. Curr Med Chem 11:313-327, Feb. 2004.
46. Tranulis C., et al.: Benefits and risks of antipsychotic polypharmacy: An evidence based review of the literature. Drug Saf 31(1):7-20, 2008.
47. Anil-Yagcioglu A., et al.: A double blind controlled study of adjunctive treatment with risperidone in schizophrenic patients partially responsive to clozapine: Efficacy and safety. J Clin Psychiatry 66:63-72, Jan. 2005.
48. Freudenreich O., et al.: Risperidone augmentation for schizophrenia partially responsive to clozapine: A double-blind, placebo-controlled trial. Schizophr Res 92:90-94, May 2007.
49. Horner W.G., et al.: Clozapine alone versus clozapine and risperidone with refractory schizophrenia. N Engl J Med 354:472-482, Feb. 2006.
50. Josiassen R.C., et al.: Clozapine augmentation with risperidone in the treatment of schizophrenia: A randomized, double blind, placebo controlled trial. Am J Psychiatry 162:130-136, Jan. 2005.
51. Kotler M., et al.: Sulpiride augmentation of olanzapine in the management of treatment-resistant chronic schizophrenia: Evidence for improvement of mood symptomatology. Int Clin Psychopharmacol 19:23-26, Jan. 2004.
52. Shiloh R., et al.: Sulpiride augmentation in people with schizophrenia partially responsive to clozapine: A double-blind, placebo-controlled study. Br J Psychiatry 171:569-573, Dec. 1997.
53. Agelink M.W, et al.: Clozapine with amisulpride for refractory schizophrenia (letter). Am J Psychiatry 161:924-925, May 2004.
54. de Groot I.W., et al.: Addition of risperidone to clozapine therapy in chronically psychotic inpatients. J Clin Psychiatry 62:129-130, Feb. 2001.
55. Friedman J., et al.: Pimozide augmentation for the treatment of schizophrenic patients who are partially responsive to clozapine. Biol Psychiatry 42:522-523, Sep. 15, 1997.
56. Henderson D.C., Goff D.C.: Risperidone as an adjunct to clozapine therapy in chronic schizophrenics. J Clin Psychiatry 57:395-397, Sep. 1996.
57. Megna J.L., et al.: A study of polypharmacy with second generation antipsychotics in patients with severe and persistent mental illness. J Psychiatr Pract 13:129-137, Mar. 2007.
58. Munro J., et al.: Amisulpride augmentation of clozapine: An open non-randomized study in patients with schizophrenia partially responsive to clozapine. Acta Psychiatr Scand 110:292-298, Oct. 2004.
59. Taylor C.G., et al.: An open trial of risperidone augmentation of partial response to clozapine. Schizophr Res 48:155-158, Mar. 1, 2001.
60. Ziegenbein M., et al.: Aripiprazole augmentation of clozapine in treatment resistant schizophrenia. Clin Drug Invest 26(3):117-124, 2006.
61. Ziegenbein M., et al.: Combination of clozapine and Ziprasidone in treatment resistant schizophrenia: An open clinical study. Clin Neuropharmacol 28:220-224, Sep.-Oct. 2005.
62. Potkin S.G., et al.: The safety and pharmacokinetics of quetiapine when co-administered with haloperidol, risperidone or thioridazine. J Clin Psychopharmacol 22:121-130, Apr. 2002.
63. Potter W.Z., et al.: Clozapine in China: A review and preview of US/PCR collaboration. Psychopharmacohgy (Berl) 99(suppl.):S87-S91, 1989.
64. Shim J.C., et al.: Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic induced hyperprolactinemia: A placebo controlled trial. Am J Psychiatry 164:1404-1410, Sep. 2007.
65. Centorrino F., et al.: Use of combinations of antipsychotics: McLean Hospital inpatients, 2002. Hum Psychopharmacol 20:485-492, Oct. 2005.
66. Centorrino F., et al.: Multiple vs. single antipsychotic agents for hospitalized psychiatric patients: Case-control study of risks versus benefits. Am J Psychiatry 161:700-706, Apr. 2004.
67. Correll C.U., et al.: Does antipsychotic polypharmacy increase the risk of metabolic syndrome? Schizophr Res 89:91-100, Jan. 2007.
68. Henderson D.C., et al.: Risperidone added to clozapine: Impact on serum prolactin levels. J Clin Psychiatry 62:605-608, Aug. 2001.
69. Knight R.G., et al.: A double blind comparison of thiothixene and a trifluoperazine/chlorpromazine composite in the treatment of chronic schizophrenia. N Z Med J 89:302-304, Act. 1979.
70. Nishikawa T., et al.: Prophylactic effects of neuroleptics in symptom free schizophrenics: Roles of dopaminergic and noradrenergic blockers. Biol Psychiatry 20:1161-1166, Nov. 1985.
71. Ganesan S., et al.: Antipsychotic polypharmacy does not increase the risk for side effects. Schizophr Res 98:323-324, Jan. 2008.
72. Henderson D.C., et al.: An exploratory open-label trial of aripiprazole as an adjuvant to clozapine therapy in chronic schizophrenia. Acta Psychiatr Scand 113:142-147, Feb. 2006.
73. Joukamaa M., et al.: Schizophrenia, neuroleptic medication and mortality. Br J Psychiatry 188:122-127, Feb. 2006.
74. Reinstein M.J., et al.: Effect of clozapine-quetiapine combination therapy on weight and glycaemic control. Clin Drug Investig 18:99-104, Aug. 1999.
75. Tapp A.M., et al.: Antipsychotic polypharmacy: Do benefits justify the risks? Ann Pharmacother 39:1759-1760, Oct. 2005.
76. Waddington J.L., et al.: Mortality in schizophrenia: Antipsychotic polypharmacy and absence of adjunctive anticholinergics over the course of a 10-year prospective study. Br J Psychiatry 173:325-329, Oct. 1998.
77. Coleman E.A.: Falling through the cracks: Challenges and opportunities for improving transitional care for persons with continuous complex care needs. J Am Geriatr Soc 51:549-555, Apr. 2003.
78. Borckardt J.J., et al.: Enhancing patient safety in psychiatric settings. J Psychiatr Tract 13:355-361, Nov. 2007.
79. Sailas E., et al.: Restraint and seclusion in psychiatric inpatient wards. Curr Opin Psychiatry 8:555-559, Sep. 2005.
80. Suzuki T., et al.: Revising polypharmacy to a single antipsychotic regimen for patients with chronic schizophrenia. Int J Neuropsychopharmacol 7:133-142, Jun 2004.
81. Zhu B., et al.: Cost of antipsychotic polypharmacy in the treatment ot schizophrenia. BMC Psychiatry 8:19, Apr. 4, 2008.
82. Valuck R.J., et al.: How expensive is antipsychotic polypharmacy? Experience from five US Medicaid programs. Curr Med Res Opin 23:2567-2576, Oct. 2007.
83. Semansky R.M., et al.: Medicaid Formulary Policies: Access to High-Cost Mental Health Medications. 1999. http://www.bazelon.org/issues/ medicaid/publications/formulary.htm (last accessed Aug. 21, 2008).